You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)與鎂信健康達成戰略合作
阿思達克 01-13 16:12
亞盛醫藥-B(06855.HK)宣佈,與上海鎂信健康科技日前達成戰略合作,根據合作協議,雙方將基於各自在醫藥創新、商業化、創新支付等方面的優勢開展深度合作和探索創新,致力打造更完善的醫療服務體驗,打通患者獲得創新藥物的最後一公裏,惠及更多患者。 公司表示,全資附屬自研的原創1類新藥奧雷巴替尼片(耐立克)去年獲國家藥品監督管理局批準上市,用於治療任何酪氨酸激(酉每)抑制劑耐藥,是中國首個且唯一獲批上市的第三代BCR-ABL抑制劑,將爲此次戰略合作的重點。 亞盛醫藥董事長兼CEO楊大俊指,耐立克是能夠解決無藥可醫、滿足臨牀急需的創新藥品,提升其可及性和可負擔性至關重要,鎂信健康專注於建立藥品支付領域的多層次保障體系,致力通過金融創新方案助力患者解決醫療支付問題,預期能夠爲耐立克的可及提供更加靈活和多元的支持。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account